Myelodysplastic Syndrome (MDS) Market Analysis
Myelodysplastic Syndrome being one of the rare blood cancers, has been into the limelight of researchers since a decade as it is not merely a cancer, indeed, needs their utmost attention towards the curative treatment before the patients succumb to this deadly disease. Fortunately, the beginning of 21st century has seen a lot coming out from the research such as approvals of hypomethylating agents, immunomodulatory agent’s erythroid maturation agents and others where blood transfusions, erythropoietin-stimulating agents (ESAs), recombinant human granulocyte colony-stimulating factor (G-CSF) or GM-CSF were considered to be the only options for the disease; even in relapsed cases.
Through Myelodysplastic Syndrome whitepaper, Delveinsight will draw your attention towards the evolution history of the disease, from the disease classification in the past to the paradigm shift in the current treatment. This paper also highlights how several emerging therapies in the pipeline might impact the current treatment regimens, cost analysis of recently approved therapies, special emphasis on therapies with breakthrough designations, insights on revised prognostic system along with discussion on Myelodysplastic Syndrome types. In addition, the paper also underlines the various clinical unmet needs in the area which remain unaddressed till today. Through this whitepaper, the reader can get an overview of the future developments in the universe of MDS therapies.
Know more about What's covered:
- Sneak peek into the past
- Why is MDS known as a Syndrome?
- Revision of Prognostic Scoring System
- Active players involved
- Emerging therapies deep diving
- Potential Emerging players targeting mutations in MDS space
- Change in Treatment Paradigm
- Are these therapies pocket-friendly for patients
- Estimated Revenue of Inqovi and Reblozyl
- Summary table comprising of emerging therapies